VIP and migraine disorder: In a randomized clinical trial that involved the infusion of vasoactive intestinal peptide (VIP) into 12 patients, migraine-like headache was not triggered in migraine patients, although there was vasodilation of the superficial temporal artery (Rahmann et al., 2008).